Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 227
Filter
Add more filters

Complementary Medicines
Publication year range
1.
J Med Food ; 27(6): 477-487, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38498802

ABSTRACT

Obesity is a threat to public health and effective new medications are required. Platycodonis Radix (PR) is a traditional medicinal/dietary plant with activities against obesity. Using mice given a diet rich in fat, the antiobesity components of PR were identified and their molecular mechanisms were clarified further in this investigation. Initially, the impacts of PR fractions on liver histology and biochemical markers were assessed. Subsequently, the degrees of lipogenic and lipolytic gene and protein expressions were determined. Oral administration of PR polysaccharides (PG) (0.80 g/kg body weight) improved liver function (alanine aminotransferase and aspartate aminotransferase) and its antioxidant activities (total superoxide dismutase, glutathione peroxidase, and malondialdehyde), as well as alleviated blood lipid (total cholesterol, total triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) values, inflammatory systemic (TNF-α and IL-1ß), and histological abnormalities within the liver. Furthermore, PG administration downregulated the expression for lipogenic genes (ACC and FAS) and upregulated the expression for the lipolytic gene (PPARα, LPL, CPT1, and HSL). Importantly, PG raised AMPK phosphorylation and decreased SREBP-1c protein synthesis. Thus, it is possible that PG stimulates the AMPK-LPL/HSL path (lipolytic route) plus the AMPK-ACC/PPARα-CPT1 path (associated to ß-oxidation of fatty acids), while inhibiting the AMPK/(SREBP-1c)-ACC/FAS path (lipogenic route). In summary, PG has the ability to regulate lipid metabolism, and it may be useful to pharmacologically activate AMPK with PG to prevent and cure obesity.


Subject(s)
Anti-Obesity Agents , Diet, High-Fat , Liver , Mice, Inbred C57BL , Obesity , Plant Extracts , Platycodon , Animals , Diet, High-Fat/adverse effects , Obesity/metabolism , Obesity/drug therapy , Male , Anti-Obesity Agents/pharmacology , Anti-Obesity Agents/administration & dosage , Mice , Platycodon/chemistry , Liver/drug effects , Liver/metabolism , Plant Extracts/pharmacology , Plant Extracts/administration & dosage , Humans , Sterol Regulatory Element Binding Protein 1/metabolism , Sterol Regulatory Element Binding Protein 1/genetics , Plant Roots/chemistry , PPAR alpha/metabolism , PPAR alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/genetics , Polysaccharides/pharmacology , Polysaccharides/administration & dosage , Lipogenesis/drug effects , Lipolysis/drug effects , Triglycerides/metabolism , Triglycerides/blood , Alanine Transaminase/metabolism , Alanine Transaminase/blood
2.
Food Funct ; 13(5): 2925-2937, 2022 Mar 07.
Article in English | MEDLINE | ID: mdl-35191457

ABSTRACT

Obesity has been reported to be associated with gut microbiome dysbiosis. seabuckthorn fruits have traditionally been used in Tibetan foods and medicines for thousands of years. Seabuckthorn polysaccharide (SP) is one of the main functional components in seabuckthorn fruits. However, the effects of SP on a high-fat diet (HFD)-induced obesity have not yet been elucidated. The purpose of this study is to explore the amelioration effect of SP on obesity induced by HFD and to reveal its mechanism of gut microbiota and its metabolites. Results showed that 12-week SP (0.1%, w/w) dietary supplementation could significantly reduce body weight gain, serum lipid level and liver triglycerides level in obese mice. Notably, the SP treatment elevated p-AMPKα and PPARα proteins expression stimulated the phosphorylation of ACC1 and inhibited the protein expression of FAS, PPARγ, and CD36 in the mice liver. Further, SP also reorganized the gut microbiome by up-regulating the proportion of Muribaculaceae_unclassified, Bifidobacterium, Rikenellaceae_RC9_gut_group, Alistipes, and Bacteroides, and down-regulating the abundance of Lactobacillus, Firmicutes_unclassified, Dubosiella Bilophila, and Streptococcus in HFD-induced obese mice. Moreover, the production of microbial metabolites short-chain fatty acids (SCFAs) in feces has also increased. In addition, correlation analysis results showed that obesity-ameliorating effects of SP were highly associated with levels of SCFAs in feces. Therefore, the regulation of SP on liver lipid metabolism may be due to the variation of the gut microbiome and raised production of SCFAs. These results indicate that SP could play the part of a potential nutraceutical for ameliorating obesity through regulation of the gut-liver axis.


Subject(s)
Anti-Obesity Agents/pharmacology , Dietary Supplements , Hippophae , Polysaccharides/pharmacology , Animals , Anti-Obesity Agents/administration & dosage , Anti-Obesity Agents/chemistry , Diet, High-Fat , Disease Models, Animal , Gastrointestinal Microbiome/drug effects , Lipid Metabolism/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Obesity/prevention & control , Polysaccharides/administration & dosage , Polysaccharides/chemistry , Weight Gain/drug effects
3.
J Microbiol Biotechnol ; 31(7): 1011-1021, 2021 Jul 28.
Article in English | MEDLINE | ID: mdl-34099594

ABSTRACT

The root bark of Ulmus davidiana var. japonica (Japanese elm) is used in Korea and other East Asian countries as a traditional herbal remedy to treat a variety of inflammatory diseases and ailments such as edema, gastric cancer and mastitis. For this study, we investigated the lipid metabolism and anti-obesity efficacy of ethyl alcohol extract of Ulmus davidiana var. japonica root bark (UDE). First, HPLC was performed to quantify the level of (+)-catechin, the active ingredient of UDE. In the following experiments, cultured 3T3-L1 pre-adipocytes and high-fat diet (HFD)-fed murine model were studied for anti-obesity efficacy by testing the lipid metabolism effects of UDE and (+)-catechin. In the test using 3T3-L1 pre-adipocytes, treatment with UDE inhibited adipocyte differentiation and significantly reduced the production of adipogenic genes and transcription factors PPARγ, C/EBPα and SREBP-1c. HFD-fed, obese mice were administered with UDE (200 mg/kg per day) and (+)-catechin (30 mg/kg per day) by oral gavage for 4 weeks. Weight gain, epididymal and abdominal adipose tissue mass were significantly reduced, and a change in adipocyte size was observed in the UDE and (+)-catechin treatment groups compared to the untreated control group (***p < 0.001). Significantly lower total cholesterol and triglyceride levels were detected in UDE-treated HFD mice compared to the control, revealing the efficacy of UDE. In addition, it was found that lipid accumulation in hepatocytes was also significantly reduced after administration of UDE. These results suggest that UDE has significant anti-obesity and lipid metabolism effects through inhibition of adipocyte differentiation and adipogenesis.


Subject(s)
Anti-Obesity Agents/pharmacology , Diet, High-Fat/adverse effects , Lipid Metabolism/drug effects , Obesity/drug therapy , Ulmus/chemistry , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Adipocytes/metabolism , Adipogenesis/drug effects , Adipogenesis/genetics , Animals , Anti-Obesity Agents/administration & dosage , Anti-Obesity Agents/chemistry , Catechin/administration & dosage , Catechin/pharmacology , Cell Differentiation/drug effects , Hepatocytes/drug effects , Hepatocytes/metabolism , Lipids/blood , Mice , Obesity/etiology , Obesity/metabolism , Obesity/pathology , Plant Bark/chemistry , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Roots/chemistry , Weight Gain/drug effects
4.
Food Funct ; 12(9): 4105-4116, 2021 May 11.
Article in English | MEDLINE | ID: mdl-33977918

ABSTRACT

Epigallocatechin-3-gallate (EGCG) and caffeine constitute the most effective ingredients of weight loss in tea. However, whether combination of EGCG and caffeine exhibits anti-obesity synergy remains unclear. Here, we showed low-doses of EGCG and caffeine used in combination led to synergistic anti-obesity effects equivalent to those of high-dose EGCG. Furthermore, combination treatment exhibited a synergistic effect on altering gut microbiota, including decreased Firmicutes level and increased Bifidobacterium level. Other notable effects of combination treatment included synergistic effects on: increasing fecal acetic acid, propionic acid, and total SCFAs; decreasing expression of GPR43; and increasing microbial bile salt hydrolase gene copies in the gut, facilitating generation of unconjugated BAs and enhancing fecal BA loss. Additionally, combination treatment demonstrated synergistic effects toward increasing the expression of hepatic TGR5 and decreasing the expression of intestinal FXR-FGF15, resulting in increased expression of hepatic CYP7A1. Thus, the synergistic effect may be attributed to regulation of gut microbiota and BA metabolism.


Subject(s)
Anti-Obesity Agents/administration & dosage , Bile Acids and Salts/metabolism , Caffeine/administration & dosage , Catechin/analogs & derivatives , Gastrointestinal Microbiome/drug effects , Obesity/drug therapy , Animals , Bile Acids and Salts/analysis , Catechin/administration & dosage , Cholesterol 7-alpha-Hydroxylase/metabolism , Drug Synergism , Drug Therapy, Combination , Fatty Acids, Volatile/analysis , Fatty Acids, Volatile/metabolism , Feces/chemistry , Liver/metabolism , Male , Rats , Rats, Sprague-Dawley , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, G-Protein-Coupled/metabolism
5.
Physiol Res ; 70(2): 161-168, 2021 04 30.
Article in English | MEDLINE | ID: mdl-33992045

ABSTRACT

This paper reviews provenance, chemical composition and properties of tea (Camelia sinensis L.) and coffee (Coffee arabica, L. and Coffeacaniphora, L.), their general health effects, as well as the currently available knowledge concerning their action on fat storage, physiological mechanisms of their effects, as well as their safety and recommended dosage for treatment of obesity. Both tea and coffee possess the ability to promote health and to prevent, to mitigate and to treat numerous disorders. This ability can be partially due to presence of caffeine in both plants. Further physiological and medicinal effects could be explained by other molecules (theaflavins, catechins, their metabolites and polyphenols in tea and polyphenol chlorogenic acid in coffee). These plants and plant molecules can be efficient for prevention and treatment of numerous metabolic disorders including metabolic syndrome, cardiovascular diseases, type 2 diabetes and obesity. Both plants and their constituents can reduce fat storage through suppression of adipocyte functions, and support of gut microbiota. In addition, tea can prevent obesity via reduction of appetite, food consumption and food absorption in gastrointestinal system and through the changes in fat metabolism.


Subject(s)
Anti-Obesity Agents/administration & dosage , Coffee , Health Status , Obesity/prevention & control , Phytochemicals/administration & dosage , Tea , Adiposity/drug effects , Animals , Anti-Obesity Agents/adverse effects , Appetite Regulation/drug effects , Coffee/adverse effects , Humans , Lipid Metabolism/drug effects , Obesity/diagnosis , Obesity/physiopathology , Phytochemicals/adverse effects , Tea/adverse effects , Weight Gain/drug effects
6.
Nutrients ; 13(3)2021 Mar 10.
Article in English | MEDLINE | ID: mdl-33801901

ABSTRACT

Trilobatin was identified as the primary bioactive component in the Lithocarpus polystachyus Rehd (LPR) leaves. This study explored the antiobesity effect of trilobatin from LPR leaves and its influence on gut microbiota in obese rats. Results showed that trilobatin could significantly reduce body and liver weight gain induced by a high-fat diet, and the accumulation of perirenal fat, epididymal fat, and brown fat of SD (Male Sprague-Dawley) obese rats in a dose-independent manner. Short-chain fatty acids (SCFAs) concentrations increased, especially the concentration of butyrate. Trilobatin supplementation could significantly increase the relative abundance of Lactobacillus, Prevotella, CF231, Bacteroides, and Oscillospira, and decrease greatly the abundance of Blautia, Allobaculum, Phascolarctobacterium, and Coprococcus, resulting in an increase of the ratio of Bacteroidetes to Firmicutes (except the genera of Lactobacillus and Oscillospira). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway predicted by the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) indicated the different relative metabolic pathways after trilobatin supplementation. This study may reveal the contribution of gut microbiota to the antiobesity effect of trilobatin from LPR leaves and predict the potential regulatory mechanism for obesity induced by a high-fat diet.


Subject(s)
Anti-Obesity Agents/pharmacology , Diet, High-Fat , Dietary Supplements , Flavonoids/pharmacology , Gastrointestinal Microbiome/drug effects , Obesity/microbiology , Polyphenols/pharmacology , Animals , Anti-Obesity Agents/administration & dosage , Bacteroidetes/classification , Bacteroidetes/growth & development , Body Weight/drug effects , Fagaceae/chemistry , Fatty Acids, Volatile/analysis , Firmicutes/classification , Firmicutes/growth & development , Flavonoids/administration & dosage , Liver/drug effects , Male , Metabolic Networks and Pathways/drug effects , Obesity/etiology , Obesity/metabolism , Organ Size/drug effects , Plant Leaves/chemistry , Polyphenols/administration & dosage , Rats , Rats, Sprague-Dawley
7.
J Trace Elem Med Biol ; 66: 126736, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33711700

ABSTRACT

BACKGROUND: Obesity is one of the most popular topic in the field of research. In order to defeat this highly widespread disease, the mechanism of fat accumulation at the molecular level and its elimination are crucial. The use of boron has been showing promising results during the recent years. METHODS: In this study, anti-obesity potential of Sodium Pentaborate Pentahydrate (SPP) used as a dietary supplement on BALB/c mice fed with a high-fat diet was evaluated. Mice were divided into four groups with different diets, consisting of a normal diet, a high-fat diet (HFD) (containing 60 % fat), a HFD-supplemented with 0.5 mg/g body weight (BW) of SPP and a HFD-supplemented with 1.5 mg/g body weight (BW) of SPP. The animals were then observed for 10 weeks and physically monitored, and were sacrificed at the end of the experiment for physical and physicochemical evaluation. RESULTS: According to the physical parameters measured -body weight, food and water intake ratios-, the results indicate that SPP decreased weight gain in a dose dependent manner. Measurement of the hormone levels in the blood and fat accumulation in organs of mice also supported the anti-obesity effects of SPP. Expressions of adipogenesis related genes were also negatively regulated by SPP administration in white adipose tissue (WAT) tissue. CONCLUSION: These findings promise a treatment approach and drug development that can be used against obesity when SPP is used in the right doses. As a future aspect, clinical studies with SPP will reveal the effect of boron derivatives on obesity.


Subject(s)
Anti-Obesity Agents/pharmacology , Borates/pharmacology , Lipids/antagonists & inhibitors , Obesity/drug therapy , Administration, Oral , Animals , Anti-Obesity Agents/administration & dosage , Borates/administration & dosage , Diet, High-Fat/adverse effects , Dose-Response Relationship, Drug , Female , Mice , Mice, Inbred BALB C , Obesity/chemically induced
8.
Pak J Biol Sci ; 24(1): 99-111, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33683036

ABSTRACT

BACKGROUND AND OBJECTIVE: Red onions are one of the most consumed vegetable crops in Egypt, their peel is rich in antioxidants that reduce the risk of diabetes and weight is lost. The study aimed to extract bioactive compounds present in Egyptian Red Onion Peels Waste (ROPE), increasing their efficiency and protecting them using nano-encapsulation as new emerging technology. MATERIALS AND METHODS: Extraction of the bioactive compounds in the Egyptian red onion peels was carried out to study their antioxidant activity before and after nano-emulsions and micro-capsules, their physical and morphological characteristics with their different nano-forms and their application in sponge cake products. The biological evaluation was also studied using rats and statistical analysis. RESULTS: The results showed that the ethanol extracts high content of bioactive compounds compared to water extract and that the use of nano-technique as a new emerging technology in form of nano-emulsion using sodium alginate with diameter size between 8.3-13.6 nm. Results also indicated that there was an improvement in the efficiency of antioxidant activity at high-temperature degrees during baking, with a melting point of up to 223.64°C, with an improvement in the blood sugar levels of diabetic rats and a significant decrease in body weight. CONCLUSION: Nano treatments had a protective effect on liver, safety towards kidneys, lowering blood sugar, improving the efficiency comparing to the other samples and were more acceptable to the consumer.


Subject(s)
Anti-Obesity Agents/administration & dosage , Blood Glucose/drug effects , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/administration & dosage , Onions , Plant Extracts/administration & dosage , Weight Loss/drug effects , Administration, Oral , Animal Feed , Animals , Anti-Obesity Agents/isolation & purification , Antioxidants/administration & dosage , Antioxidants/isolation & purification , Biomarkers/blood , Blood Glucose/metabolism , Capsules , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/diagnosis , Drug Compounding , Hypoglycemic Agents/isolation & purification , Male , Onions/chemistry , Plant Extracts/isolation & purification , Plant Roots , Rats
9.
Nutrients ; 13(2)2021 Jan 29.
Article in English | MEDLINE | ID: mdl-33572973

ABSTRACT

Nowadays, obesity is one of the great nutritional problems facing public health. The prevalence of this pathology has increased in a worrying way over recent years, currently reaching epidemic proportions. In this context, nutritional supplements are presented as a therapeutic alternative to which more and more people are turning to. Nutritional supplements to lose weight based on the Garcinia plant, specifically on Garcinia cambogia, are commonly used. The active principle of this plant to which these properties have been attributed, is hydroxycitric acid (HCA). The aim of the present review is to gather reported data concerning the effectiveness of nutritional supplements based on Garcinia extracts on weight loss and their possible negative effects. Contradictory results have been observed regarding the effectiveness of the supplements. While statistically significant weight loss was observed in some studies, no changes were found in others. Regarding safety, although Garcinia supplements have been revealed as safe in the vast majority of the studies carried out in animal models and humans, some cases of hepatotoxicity, serotonin toxicity and mania have been reported. In conclusion, the results suggest that Garcinia-based supplements could be effective in short-term weight loss, although the data are not conclusive. In addition, the safety of the complement should be further studied.


Subject(s)
Anti-Obesity Agents/administration & dosage , Dietary Supplements , Garcinia cambogia , Obesity/therapy , Plant Extracts/administration & dosage , Animals , Anti-Obesity Agents/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Citrates/administration & dosage , Citrates/adverse effects , Humans , Mania/chemically induced , Plant Extracts/adverse effects , Serotonin/metabolism , Weight Loss/drug effects
10.
Gut Microbes ; 13(1): 1-19, 2021.
Article in English | MEDLINE | ID: mdl-33550882

ABSTRACT

Betaine is a natural compound present in commonly consumed foods and may have a potential role in the regulation of glucose and lipids metabolism. However, the underlying molecular mechanism of its action remains largely unknown. Here, we show that supplementation with betaine contributes to improved high-fat diet (HFD)-induced gut microbiota dysbiosis and increases anti-obesity strains such as Akkermansia muciniphila, Lactobacillus, and Bifidobacterium. In mice lacking gut microbiota, the functional role of betaine in preventing HFD-induced obesity, metabolic syndrome, and inactivation of brown adipose tissues are significantly reduced. Akkermansia muciniphila is an important regulator of betaine in improving microbiome ecology and increasing strains that produce short-chain fatty acids (SCFAs). Increasing two main members of SCFAs including acetate and butyrate can significantly regulate the levels of DNA methylation at host miR-378a promoter, thus preventing the development of obesity and glucose intolerance. However, these beneficial effects are partially abolished by Yin yang (YY1), a common target gene of the miR-378a family. Taken together, our findings demonstrate that betaine can improve obesity and associated MS via the gut microbiota-derived miR-378a/YY1 regulatory axis, and reveal a novel mechanism by which gut microbiota improve host health.


Subject(s)
Anti-Obesity Agents/pharmacology , Betaine/pharmacology , Gastrointestinal Microbiome/drug effects , MicroRNAs/genetics , Obesity/prevention & control , Animals , Anti-Obesity Agents/administration & dosage , Bacteria/classification , Bacteria/growth & development , Bacteria/metabolism , Betaine/administration & dosage , Diet, High-Fat/adverse effects , Dietary Supplements , Fatty Acids, Volatile/metabolism , Female , Metabolic Syndrome/etiology , Metabolic Syndrome/genetics , Metabolic Syndrome/microbiology , Metabolic Syndrome/prevention & control , Mice , Obesity/etiology , Obesity/genetics , Obesity/microbiology , YY1 Transcription Factor/genetics
11.
Molecules ; 26(2)2021 Jan 09.
Article in English | MEDLINE | ID: mdl-33435518

ABSTRACT

Obesity is one of the risk factors associated with cardiovascular diseases, hypertension, abnormal liver function, diabetes, and cancers. Orlistat is currently available to treat obesity, but it is associated with adverse side effects. Natural resources are widely used for obesity treatment. Hence, this study aimed to investigate the anti-obesity activity of Elateriospermum tapos (E. tapos) shell extract in obesity induced Sprague Dawley rats. The rats' obesity was induced by a high-fat (HF) diet made up of 50% standard rat pellet, 20% milk powder, 6% corn starch, and 24% ghee and a cafeteria (CAF) diet such as chicken rolls, salty biscuits, cakes, and cheese snacks. A hot aqueous method for the extraction of E. tapos shells was applied by using 500 mL of distilled water for about 24 h. Various dosages of E. tapos shell extract (10 mg/kg, 100 mg/kg, and 200 mg/kg) were used. At the end of the study, body weight, caloric intake, organ weight, lipid profile, lipoprotein lipase (LPL) activity, and histopathology analysis were carried out. E. tapos shell extract treated groups showed a reduction in body weight, positive lipid-lowering effect, decrements in triglyceride accumulation and LPL activity, and positive improvement in histopathology analysis. A dose of 200 mg/kg showed the most effective result compared to 10 mg/kg and 100 mg/kg doses.


Subject(s)
Anti-Obesity Agents/pharmacology , Euphorbiaceae/chemistry , Obesity/drug therapy , Plant Extracts/pharmacology , Administration, Oral , Animals , Anti-Obesity Agents/administration & dosage , Anti-Obesity Agents/chemistry , Body Weight/drug effects , Diet, High-Fat/adverse effects , Liver/drug effects , Liver/pathology , Male , Obesity/chemically induced , Obesity/pathology , Organ Size/drug effects , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Rats , Rats, Sprague-Dawley
12.
Nutrients ; 14(1)2021 Dec 30.
Article in English | MEDLINE | ID: mdl-35011045

ABSTRACT

Obesity caused by a positive energy balance is a serious health burden. Studies have shown that obesity is the major risk factor for many diseases like type 2 diabetes mellitus, coronary heart diseases, or various types of cancer. Therefore, the prevention and treatment of increased body weight are key. Different evidence-based treatment approaches considering weight history, body mass index (BMI) category, and co-morbidities are available: lifestyle intervention, formula diet, drugs, and bariatric surgery. For all treatment approaches, behaviour change techniques, reduction in energy intake, and increasing energy expenditure are required. Self-monitoring of diet and physical activity provides an effective behaviour change technique for weight management. Digital tools increase engagement rates for self-monitoring and have the potential to improve weight management. The objective of this narrative review is to summarize current available treatment approaches for obesity, to provide a selective overview of nutrition trends, and to give a scientific viewpoint for various nutrition concepts for weight loss.


Subject(s)
Nutritional Physiological Phenomena/physiology , Obesity/therapy , Anti-Obesity Agents/administration & dosage , Bariatric Surgery , Diet Therapy , Diet, Reducing , Eating/physiology , Energy Intake/physiology , Fasting , Female , Gastrointestinal Microbiome , Humans , Male , Nutrients/administration & dosage , Obesity/etiology , Obesity/physiopathology , Obesity/psychology , Recommended Dietary Allowances , Referral and Consultation , Weight Reduction Programs
13.
J Sci Food Agric ; 101(2): 573-581, 2021 Jan 30.
Article in English | MEDLINE | ID: mdl-32673411

ABSTRACT

BACKGROUND: Caffeine has an anti-obesity effect, although chronic excessive caffeine consumption also causes caffeinism, which is marked by increased anxiety or depression, amongst other symptoms. The present study aimed to investigate whether the addition of flavonoids such as astilbin can reduce the caffeine dose needed to inhibit obesity. RESULTS: ICR mice (n = 80) were fed with normal diet, high-fat diet (HFD), HFD supplemented with astilbin, caffeine, or astilbin + caffeine for 12 weeks. When diets supplemented with astilbin, 0.3 g kg-1 diet caffeine had the same effect as 0.6 g kg-1 diet caffeine alone, and 0.6 g kg-1 diet caffeine combined with astilbin most effectively inhibited HFD-induced obesity. Astilbin improved the anti-obesity effects of caffeine on lipid accumulation via the activation of AMP-activated protein kinase α (AMPKα). (i) Activated AMPKα decreased lipid biosynthesis by suppressing the activity or mRNA expression of 3-hydroxy-3-methylglutaryl-CoA reductase, sterol regulatory element binding protein 1c and its target gene fatty acid synthase. (ii) Activated AMPKα also up-regulated lipolysis by enhancing the expression of adipose triglyceride lipase and increasing the phosphorylation of hormone-sensitive lipase. (iii) Finally, activated AMPKα increased carnitine acyltransferase and acyl-CoA oxidase activities, which further promoted fatty acid ß-oxidation. CONCLUSION: The results obtained in the present study indicate that astilbin may decrease the effective dose of caffeine needed for an anti-obesity effect and also suggest that it suppresses fat accumulation via the activation of AMPK. © 2020 Society of Chemical Industry.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Anti-Obesity Agents/administration & dosage , Caffeine/administration & dosage , Flavonols/administration & dosage , Lipid Metabolism/drug effects , Obesity/drug therapy , AMP-Activated Protein Kinases/genetics , Animals , Anti-Obesity Agents/antagonists & inhibitors , Caffeine/antagonists & inhibitors , Diet, High-Fat/adverse effects , Dietary Supplements/analysis , Humans , Lipogenesis/drug effects , Lipolysis/drug effects , Male , Mice , Mice, Inbred ICR , Mice, Obese , Obesity/genetics , Obesity/metabolism , Obesity/physiopathology , Sterol Regulatory Element Binding Protein 1/genetics , Sterol Regulatory Element Binding Protein 1/metabolism
14.
Nutrients ; 12(11)2020 Nov 22.
Article in English | MEDLINE | ID: mdl-33266423

ABSTRACT

Nelumbinis Semen (NS, the seeds of Nelumbo nucifera) extract is a traditional Korean medicine with anti-oxidant activity. The present study examined the anti-obesity and antidiabetic effects of NS powder in high-fat diet (HFD)-induced obese C57BL/6 mice. Mice (n = 8/group) were fed a normal diet (CON), HFD, HFD containing 5% NS powder (HFD-NS5%), or HFD containing 10% NS powder (HFD-NS10%) for 12 weeks. Food intake was relatively higher in groups HFD-NS5% and HFD-NS10%, while the food efficiency ratio was highest in group HFD (p < 0.05). HFD-NS5% reduced the body weight (-39.1%) and fat weight (-26.6%), including epididymal fat and perirenal fat, and lowered the serum triglyceride levels (-20.6%) compared with HFD. Groups HFD-NS5% and HFD-NS10% showed hepatoprotective properties, reducing the serum ALT levels (p < 0.05) and fat globules (size and number) in the liver compared with group HFD. HFD-NS5% and HFD-NS10% regulated the blood glucose, improved the glucose intolerance, and showed a 12.5% and 15.0% reduction in the area under the curve (AUC) of intraperitoneal glucose tolerance test (IPGTT), and a 26.8% and 47.3% improvement in homeostatic model assessment insulin resistance (HOMA-IR), respectively, compared with HFD (p < 0.05). Regarding the expressions of genes related to anti-obesity and antidiabetes, there was a 1.7- and 1.3-fold increase in PPAR-α protein expression, 1.4- and 1.6-fold increase in PPAR-γ protein expression, and 0.7- and 0.6-fold decrease in TNF-α protein expression, respectively, following HFD-NS5% and HFD-NS10% treatments, compared with HFD, and GLUT4 protein expression increased relative to CON (p < 0.05). These results comprehensively provide the fundamental data for NS powder's functional and health-promoting benefits associated with anti-obesity and antidiabetes.


Subject(s)
Anti-Obesity Agents/administration & dosage , Drugs, Chinese Herbal/chemistry , Hypoglycemic Agents/administration & dosage , Obesity/drug therapy , Plant Extracts/administration & dosage , Animals , Blood Glucose/analysis , Diet, High-Fat , Glucose Transporter Type 4/analysis , Insulin Resistance , Lipids/blood , Liver/chemistry , Liver/drug effects , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Obesity/etiology , Obesity/pathology , PPAR alpha/analysis , PPAR gamma/analysis , Republic of Korea , Tumor Necrosis Factor-alpha/analysis , Weight Gain/drug effects
15.
Nutrients ; 12(8)2020 Aug 07.
Article in English | MEDLINE | ID: mdl-32784736

ABSTRACT

The use of dietary supplements for weight loss has gained significant momentum. Polyglucosamine, a chitosan derivative, is a dietary supplement increasingly used for weight loss. In this meta-analysis, we systematically summarized and quantified the key findings of four randomized, placebo-controlled clinical trials examining the effects of polyglucosamine supplementation and caloric restriction, and physical activity on body weight, body mass index (BMI), and waist circumference in subjects with overweight and obesity. The control group was set with a physical activity from 6-7 MET-h/week activity and up to 21 MET-h/week activity with caloric restriction. Compliance in the latter trials was reported via a follow-up questionnaire with the individual participants. The analysis included 399 subjects followed for a period ranging from 12 weeks to one year. Subjects' age ranged from 21-75 years, BMI from 26-45 kg/m2, and all were white European or Caucasian in ethnicity. The meta-analyzed mean differences for random effects showed that polyglucosamine supplementation improves weight loss by -1.78 kg [-2.78, -0.79], BMI by -1.52 kg/m2 [-3.58, 0.54], and improves waist circumference reduction by -1.45 cm [-2.77, -0.12]. In conclusion, the use of polyglucosamine supplementation in conjunction with lifestyle behavioral therapies can be effective for weight reduction. Further studies are needed to examine the long-term effects of polyglucosamine supplementation on weight loss and other metabolic parameters.


Subject(s)
Anti-Obesity Agents/administration & dosage , Dietary Supplements , Glucosamine/administration & dosage , Obesity/therapy , Overweight/therapy , Adult , Aged , Body Mass Index , Caloric Restriction/methods , Exercise/physiology , Female , Humans , Male , Middle Aged , Obesity/physiopathology , Overweight/physiopathology , Randomized Controlled Trials as Topic , Treatment Outcome , Weight Loss/drug effects , Young Adult
16.
J Nutr Biochem ; 83: 108430, 2020 09.
Article in English | MEDLINE | ID: mdl-32615488

ABSTRACT

Adipose tissue inflammation has been proposed as a central mechanism connecting obesity with its metabolic and vascular complications due to the imbalance in the expression of several hormones and adipokines. Berries rich in polyphenols and unsaturated fatty acids have been able to prevent both obesity and adipose tissue inflammation, improving metabolic functions in human subjects and animal models of obesity. Juçara has been considered a super fruit owing to its nutritional composition and relevant biological activities with an interesting response in animals. Thus, we aimed to verify the potential antiobesogenic effect of juçara supplementation in humans. We conducted a double-blind, placebo-controlled, randomized trial with 35 adults with obesity of both sexes. They were assessed for resting metabolic rate, anthropometry and body composition, blood pressure, metabolic parameters and adipokines. Subsequently, they were randomized into two groups to use or not (placebo) 5 g lyophilized juçara for 6 weeks. Supplementation with juçara was significantly effective in reducing body fat, increasing high-density lipoprotein cholesterol and doubling serum adiponectin. Besides, juçara supplementation, high-density lipoprotein cholesterol and neck circumference were predictors to explain the enhancement in adiponectin. Juçara supplementation was determinant to improve adiponectin levels, and it may be considered a novel strategy for the treatment of obesity-related metabolic diseases.


Subject(s)
Anti-Obesity Agents/administration & dosage , Artemisia/chemistry , Obesity/drug therapy , Obesity/metabolism , Plant Extracts/administration & dosage , Adipokines/blood , Adult , Blood Glucose/metabolism , Blood Pressure/drug effects , Cholesterol, HDL/blood , Double-Blind Method , Female , Fruit/chemistry , Humans , Male , Middle Aged , Obesity/physiopathology , Polyphenols/administration & dosage
17.
J Agric Food Chem ; 68(22): 6142-6153, 2020 Jun 03.
Article in English | MEDLINE | ID: mdl-32394707

ABSTRACT

Tangeretin (TAN) exhibited antilipogenic, antidiabetic, and lipid-lowering effects. However, the lipid biomarkers and the underlying mechanisms for antiobesity and cholesterol-lowering effects of TAN have not been sufficiently investigated. Herein, we integrated biochemical analysis with lipidomics to elucidate its efficacy and mechanisms in high-fat diet-fed rats. TAN at supplementation levels of 0.04 and 0.08% not only significantly decreased body weight gain, serum total cholesterol, and low-density lipoprotein cholesterol levels but also ameliorated hepatic steatosis. These beneficial effects were associated with the declining levels of fatty acids, diacylglycerols (DGs), triacylglycerols, ceramides, and cholesteryl esters by hepatic lipidomics analysis, which were attributed to downregulating lipogenesis-related genes and upregulating lipid oxidation- and bile acid biosynthesis-related genes. Additionally, 21 lipids were identified as potential lipid biomarkers, such as DGs and phosphatidylethanolamines. These findings indicated that the modulation of lipid homeostasis might be the key pathways for the mechanisms of TAN in the antiobesity and cholesterol-lowering effects.


Subject(s)
Anti-Obesity Agents/administration & dosage , Fatty Liver/drug therapy , Flavones/administration & dosage , Liver/metabolism , Obesity/drug therapy , Animals , Cholesterol/metabolism , Diet, High-Fat/adverse effects , Fatty Acids/metabolism , Fatty Liver/etiology , Fatty Liver/metabolism , Humans , Lipidomics , Liver/chemistry , Male , Obesity/etiology , Obesity/metabolism , Rats , Rats, Sprague-Dawley , Triglycerides/metabolism
18.
J Agric Food Chem ; 68(15): 4424-4436, 2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32227855

ABSTRACT

This study aimed to determine the anti-obesity effects and mechanisms of Cerasus humilis polyphenol (CHP) in C57BL/6 obese mice and 3T3-L1 cells. High-performance liquid chromatography-electrospray ionization-tandem mass spectrometry was used for the qualitative and quantitative identification of CHP components. The obese mice, induced by feeding high-fat diet (HFD), were treated with CHP (250 mg/kg/day) by gavage for 12 weeks. Orlistat was gavaged at 15.6 mg/kg bw/day, as a positive control group. The analysis revealed that the main components of CHP were procyanidin B2, cyanidin-3-glucoside, and pelargonidin-3-glucoside. CHP dietary supplementation significantly reduced body weight and improved blood lipid measurements in HFD-fed mice (p < 0.01). Moreover, it inhibited mRNA expression of miR-122, Srebp-1c, and Cpt1a (p < 0.01) and reduced hepatic lipid deposition, as seen by hematoxylin and eosin staining. CHP downregulated the protein expression of PPARγ and C/EBPα in HFD-induced obese mice and inhibited adipocyte differentiation (p < 0.01). Compared with the HFD group, CHP supplementation had an obvious anti-inflammatory effect (decreased protein expression, such as TNF-α, IL-6, and MCP1), reducing leptin levels and TNF-α secretion in serum and cells (p < 0.01). CHP significantly inhibited the expression of miR-27a/b (53.3 and 29.9%, p < 0.01) in mice retroperitoneal white adipocytes, enhancing the expression of the target gene Prdm16 and significantly upregulating Sirt1 (105.5%, p < 0.01) compared with the HFD group. Moreover, CHP supplementation effectively improved oxidative stress (ROS, T-AOC, SOD, CAT, and GSH-Px) induced by HFD in obese mice (p < 0.01). Thus, CHP mitigates adipocyte differentiation, browning of white adipocytes, and reduction of inflammation and antioxidant activity to reduce obesity. Consequently, these results provide novel insights into the anti-obesity roles of CHP in HFD-induced obesity.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Anti-Obesity Agents/administration & dosage , Obesity/drug therapy , Plant Extracts/administration & dosage , Polyphenols/administration & dosage , Prunus/chemistry , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/drug effects , Adipogenesis/drug effects , Animals , Anti-Inflammatory Agents/chemistry , Anti-Obesity Agents/chemistry , CCAAT-Enhancer-Binding Protein-alpha/genetics , CCAAT-Enhancer-Binding Protein-alpha/metabolism , Diet, High-Fat/adverse effects , Fruit/chemistry , Humans , Interleukin-6/genetics , Interleukin-6/metabolism , Liver/drug effects , Liver/metabolism , Male , Mass Spectrometry , Mice , Mice, Inbred C57BL , Mice, Obese , Obesity/genetics , Obesity/metabolism , Obesity/physiopathology , PPAR gamma/genetics , PPAR gamma/metabolism , Plant Extracts/chemistry , Polyphenols/chemistry , Sterol Regulatory Element Binding Protein 1/genetics , Sterol Regulatory Element Binding Protein 1/metabolism
19.
J Agric Food Chem ; 68(17): 4876-4883, 2020 Apr 29.
Article in English | MEDLINE | ID: mdl-32293174

ABSTRACT

Some amino acids (AAs) have been proven to suppress fat mass and improve insulin sensitivity. However, the impact of important essential AAs, threonine, lysine, and methionine, on obesity has not been clarified. In the present study, after an 8 week period of obesity induction, mice were grouped to receive either a high-fat diet (HFD) or HFD supplemented with lysine, threonine, or methionine (3% in drinking water) for another 10 weeks. The results showed that dietary supplementation with threonine significantly decreased body weight, epididymal and perirenal fat pad weights, serum concentrations of glucose, triacylglycerols, total cholesterol, and LDL-cholesterol compared to the HFD group. HOMA-IR and serum leptin and adiponectin were improved by threonine supplementation. In epididymal adipose tissue, threonine treatment significantly down-regulated the expression levels of lipogenesis and up-regulated expressions of lipolysis compared to the HFD group. Threonine addition stimulated the expression of UCP-1 and related genes in brown adipose tissue. However, lysine or methionine supplementation showed little effect on body weight, WAT weight, serum lipid profiles, and lipid-metabolism-related gene expressions of HFD-fed mice. These findings suggest that threonine inhibited fat mass and improved lipid metabolism of already obese mice, providing a potential agent in treating obesity.


Subject(s)
Anti-Obesity Agents/administration & dosage , Lipid Metabolism/drug effects , Lysine/administration & dosage , Methionine/administration & dosage , Obesity/drug therapy , Threonine/administration & dosage , Adipose Tissue, Brown/drug effects , Adipose Tissue, Brown/metabolism , Animals , Diet, High-Fat/adverse effects , Humans , Insulin Resistance , Lipogenesis/drug effects , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Obesity/genetics , Obesity/metabolism , Uncoupling Protein 1/genetics , Uncoupling Protein 1/metabolism
20.
J Med Food ; 23(3): 335-342, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32130058

ABSTRACT

This study investigated the effect of Sinetrol-XPur on weight and body fat reduction in overweight or obese Korean participants. Among 100 overweight or obese participants enrolled in a 12-week randomized, double-blinded, controlled study, 86 participants completed the trial. Participants took either two Sinetrol-XPur tablets (450 mg per tablet) or two placebo tablets once a day. Bodyweight, body fat percentage, body mass index (BMI), body fat mass, waist circumference, and various safety parameters were measured. After the 12-week intervention, a significant reduction was observed in the body fat mass (P = .030) by dual-energy X-ray absorptiometry (DEXA), body weight (P = .002), and BMI (P = .002) compared to the placebo. Body fat percentage (P = .007) by DEXA showed a significant reduction in the Sinetrol-XPur group, but no difference compared to the control group. Abdominal metabolic risks by computed tomography and blood biochemistry analysis were significantly decreased in the Sinetrol-XPur group, but there were no differences between the Sinetrol-XPur and placebo groups. Safety profiles were not different between the two groups. These results suggested that Sinetrol-XPur significantly reduced body weight, body fat mass, and BMI in obese Korean subjects, which confirms the antiobesity effect of Sinetrol-XPur in the Korean population.


Subject(s)
Anti-Obesity Agents/administration & dosage , Obesity/drug therapy , Overweight/drug therapy , Polyphenols/administration & dosage , Adult , Anti-Obesity Agents/adverse effects , Body Mass Index , Body Weight/drug effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Obesity/physiopathology , Overweight/physiopathology , Polyphenols/adverse effects , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL